Skip to main content
. Author manuscript; available in PMC: 2014 Sep 27.
Published in final edited form as: Nature. 2014 Feb 16;507(7493):519–522. doi: 10.1038/nature12978

Figure 4. Amph-vaccines maximize immunogenicity and therapeutic efficacy of polypeptide vaccines.

Figure 4

a–c, C57Bl/6 mice (n=3–4/group) were immunized with SIV-gag, Trp2, or E7 peptides (10 μg) + CpG (1.24 nmol) on d0 and d14; shown are tetramer-positive CD8+ T-cells (a) and intracellular cytokine production (b) in peripheral blood on d20. c, Trp2-specific cytotoxicity measured using an in vivo killing assay on d21. d–e, Tumor growth in C57BL/6 mice (n=8/group) inoculated with 3×105 TC-1 (d) or B16F10 (e) tumor cells and vaccinated with CpG + E7 peptide or Trp2 peptide (10 μg prime, 20 μg boost), respectively, on days indicated by arrows. Statistically-significant differences between soluble and amph-vaccines indicated by asterisks: ***, p<0.001; **, p<0.01; *, p<0.05 by one-way ANOVA with Bonferroni post-test. Shown are mean±SEM of 2–4 independent experiments.